mercredi 30 septembre 2026
RechercherExplore
fr.VIA.NEWS
Via News Knowledge File

Merck & Co., Inc.

organization80% conf.·synced Sep 30, 2026

Pharmaceutical company based in Rahway, NJ, known as MSD outside US and Canada

60
sourced metrics
660
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week High
156.45USD
Sep 29, 2026reference only
Stock Return Ytd
40.2%
Sep 29, 2026reference only
Price 52 Week Low
82.49USD
Sep 29, 2026reference only
Market Cap
368299382121USD
Sep 29, 2026reference only
Stock Price
149.28USD
Sep 29, 2026reference only
Shares Outstanding
2467171638.0shares
Jul 31, 2026reference only
Cost Of Revenue
4395000000.0USD
Jun 30, 2026reference only
Cash
6849000000.0USD
Jun 30, 2026reference only
Eps
-0.54USD_per_share
Jun 30, 2026reference only
Revenue
16607000000.0USD
Jun 30, 2026reference only
Rd Expense
9741000000.0USD
Jun 30, 2026reference only
Total Assets
129802000000.0USD
Jun 30, 2026reference only
Stockholders Equity
41933000000.0USD
Jun 30, 2026reference only
Net Income
-1335000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
3918000000.0USD
Mar 31, 2026reference only
Capex
991000000.0USD
Mar 31, 2026reference only

Stated objectives

Enroll approximately 675 patients in KANDLELIT-007 Phase 3 trial

source
target: 675 patients stated

Evaluate progression-free survival as primary endpoint in PD-L1 TPS ≥1% patients in KANDLELIT-007

source
stated

Evaluate secondary endpoints including PFS in all patients, overall survival, objective response rate, duration of response, and safety in KANDLELIT-007

source
stated

Submit regulatory filings worldwide for KEYTRUDA + Padcev combination in muscle-invasive bladder cancer based on KEYNOTE-B15/EV-304 results

source
stated

Initiate second Merck-sponsored pivotal trial of zanzalintinib and belzutifan in RCC

source
stated

Full-year sales forecast

source
target: $64.5 billion to $65 billion by 2025-12-31 00:00:00stated

Full-year EPS forecast

source
target: $8.93 to $8.98 by 2025-12-31 00:00:00stated

Improving outcomes and addressing significant unmet needs for patients with hematologic neoplasms and malignancies

source
stated

Become the premier research-intensive biopharmaceutical company in the world

source
stated

Deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals

source
stated

Relationship graph · 660 connections

Developed by
267
Competes with
67
Employs
46
acquired by
42
Partnered with
41
Covered by
28
regulates
28
headquartered in
27
headquartered in
Rahway, New Jersey
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
The Agentic Takeover of the CFO's Office
Enterprise finance software vendors—BlackLine, OneStream, Numero AI, and Oracle—are racing to embed autonomous AI agents into core financial operations (close, consolidation, reporting), backed by consolidation M&A (Numero-Royu, BlackLine-WiseLayer), fresh leadership hires, and survey data showing nearly a quarter of CFOs plan to boost AI spending over 50%. Adoption momentum is strong even as at least one bellwether (Oracle) sees its stock lag year-to-date, suggesting the market hasn't yet fully priced in the shift from AI-as-feature to AI-as-agent in finance.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Morgan Stanley & Co. LLC
Two significantly different EPS values (10.21 vs 2.68 USD_per_share) are reported for Morgan Stanley on the same observation date (2025-12-31). Fact A specifies FY 2025, while Fact B's 'N/A' fiscal period is ambiguous. If both represent FY 2025 annual EPS, these values directly conflict. The magnitude of the difference (3.8x) is too large to attribute to rounding or minor calculation variations. The missing fiscal period in Fact B raises data quality concerns, but same-date observation + same attribute should reference the same period.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,984
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,984 faits vérifiés avec la source5,315 documents sources archivés
Interrogez ces données → isubstrate.com